MedCity News April 11, 2021
Digital health startup Better Therapeutics plans to go public through a SPAC merger that would value it at $187 million. The company is currently running a pivotal study to see if its app-based program could be used as a treatment for type 2 diabetes.
Better Therapeutics, which is developing digital therapeutics for patients with chronic conditions, plans to go public in a blank-check deal that would value the startup at $187 million.
It will merge with Mountain Crest Acquisition Corp. II, a publicly-traded company with no assets of its own, to go public. Better Therapeutics expects to raise $113 million through the deal, including $50 million from private investors Farallon Capital Management, RS Investments, Sectoral Asset Management, and Monashee...
Today's Sponsors
Today's Sponsor